Thirty years in, the U.S., indeed the planet, is making great strides in HIV and AIDS research. Dr. Fauci's vision of an AIDS-free generation will only be realized with innovative biologic and biosimilar medicines that are effective in and accessible by all affected populations.
WASHINGTON -- A few hours after the Supreme Court upheld his signature health care legislation last week, President Barack Obama approached a White Ho...
The U.S. pharmaceutical industry has worked hard to become an international leader in the production of biotech drugs. But as the nation introduces these medicines, we need to ensure that safety protocols are in place -- so that every patient has the opportunity to get healthy.
Drug shortages are a complex problem with multiple causes, not least of all manufacturing issues that can affect the safety of injectable medicines like biologics.
Today, too many families face President Reagan's "long goodbye" -- and too many Alzheimers' victims know, even as the disease begins to rob them of their memories, of the pain their families will face.
It is crucial that the health care communities in both the public and private sector transform their data collection and testing approaches to account for the overall changing face of the American population.
What's the right length for data exclusivity? The current law says innovator drug makers have twelve years; in the European Union, it's ten; and the 2012 budget proposes seven. Who's right?
In America, a family should never be forced into bankruptcy because a child gets sick. In America, an Ohio family shouldn't be denied coverage if it r...
Biologics are an exciting new world of medicine. But the EMA's new guidelines should put patient safety first by requiring biosimilars to be held to the same safety and standards as the original drug.
As a matter of common sense, the FDA's process for biosimilars shouldn't sacrifice patient safety.
You know a health care bill isn't right for the American people when it carves out a legal monopoly for Big Pharma and Botox. Our Congressional leaders should be capable of more.
Legislation concerning the changes for the drug approval process on a special type of medicine (biologic medicines) could provide huge savings -- a major need with health care reform.
Pelosi made a choice about the lifesaving biologic drugs I took when I was in chemotherapy that will cost many fellow breast cancer survivors everything they own, and quite possibly their lives.
Thank you, Rep. Eshoo, for your commitment to having a bill that does not allow for "evergreening." Now the question becomes -- how are we going to get one?
The United States will only realize this potential and remain the global leader in medical innovation if we maintain a strong environment for investment in the newest wave - biopharmaceuticals, also known as biologics.
The public option has received the lion's share of attention in the health care debate, but there's an equally important issue relating to generic drugs that could mean lifesaving drugs remain too expensive for all but the wealthy.
In Congress, I will work to support affordable prices on biologics, so that victims of cancer, HIV, diabetes, Parkinsons, rheumatoid arthritis, and multiple sclerosis can afford the medicine they need to stay alive.
For nearly three decades, too many people have died and millions more are living with HIV/AIDS' painful realities. Stated simply, it is far from over.
